• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, June 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Stem Cells

Patient stem cells used to make ‘heart disease-on-a-chip’

Bioengineer by Bioengineer
May 12, 2014
in Stem Cells
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Harvard scientists have merged stem cell and ‘organ-on-a-chip’ technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, as it is working proof that a chunk of tissue containing a patient’s specific genetic disorder can be replicated in the laboratory.

Kevin Kit Parker

Kevin Kit Parker

The work, published in Nature Medicine, is the result of a collaborative effort bringing together scientists from the Harvard Stem Cell Institute, the Wyss Institute for Biologically Inspired Engineering, Boston Children’s Hospital, the Harvard School of Engineering and Applied Sciences, and Harvard Medical School. It combines the ‘organs-on-chips’ expertise of Kevin Kit Parker, PhD, and stem cell and clinical insights by William Pu, MD.

Using their interdisciplinary approach, the investigators modeled the cardiovascular disease Barth syndrome, a rare X-linked cardiac disorder caused by mutation of a single gene called Tafazzin, or TAZ. The disorder, which is currently untreatable, primarily appears in boys, and is associated with a number of symptoms affecting heart and skeletal muscle function.

The researchers took skin cells from two Barth syndrome patients, and manipulated the cells to become stem cells that carried these patients’ TAZ mutations. Instead of using the stem cells to generate single heart cells in a dish, the cells were grown on chips lined with human extracellular matrix proteins that mimic their natural environment, tricking the cells into joining together as they would if they were forming a diseased human heart. The engineered diseased tissue contracted very weakly, as would the heart muscle seen in Barth syndrome patients.

The investigators then used genome editing—a technique pioneered by Harvard collaborator George Church, PhD—to mutate TAZ in normal cells, confirming that this mutation is sufficient to cause weak contraction in the engineered tissue. On the other hand, delivering the TAZ gene product to diseased tissue in the laboratory corrected the contractile defect, creating the first tissue-based model of correction of a genetic heart disease.

“You don’t really understand the meaning of a single cell’s genetic mutation until you build a huge chunk of organ and see how it functions or doesn’t function,” said Parker, who has spent over a decade working on ‘organs-on-chips’ technology. “In the case of the cells grown out of patients with Barth syndrome, we saw much weaker contractions and irregular tissue assembly. Being able to model the disease from a single cell all the way up to heart tissue, I think that’s a big advance.”

Furthermore, the scientists discovered that the TAZ mutation works in such a way to disrupt the normal activity of mitochondria, often called the power plants of the cell for their role in making energy. However, the mutation didn’t seem to affect overall energy supply of the cells. In what could be a newly identified function for mitochondria, the researchers describe a direct link between mitochondrial function and a heart cell’s ability to build itself in a way that allows it to contract.

“The TAZ mutation makes Barth syndrome cells produce an excess amount of reactive oxygen species or ROS—a normal byproduct of cellular metabolism released by mitochondria—which had not been recognized as an important part of this disease,” said Pu, who cares for patients with the disorder.

“We showed that, at least in the laboratory, if you quench the excessive ROS production then you can restore contractile function,” Pu added. “Now, whether that can be achieved in an animal model or a patient is a different story, but if that could be done, it would suggest a new therapeutic angle.”

His team is now trying to translate this finding by doing ROS therapy and gene replacement therapy in animal models of Barth syndrome to see if anything could potentially help human patients. At the same time, the scientists are using their human ‘heart disease-on-a-chip’ as a testing platform for drugs that are potentially under trial or already approved that might be useful to treat the disorder.

“We tried to thread multiple needles at once and it certainly paid off,” Parker said. “I feel that the technology that we’ve got arms industry and university-based researchers with the tools they need to go after this disease.”

Both Parker and Pu, who first talked about collaborating at a 2012 Stockholm conference, credit their partnership and scientific consilience for the success of this research. Parker asserted that the ‘organs-on-chips’ technology that has been a flagship of his lab only worked so fast and well because of the high quality of Pu’s patient-derived cardiac cells.

“When we first got those cells down on the chip, Megan, one of the joint first authors, texted me ‘this is working,'” he recalled. “We thought we’d have a much harder fight.”

“When I’m asked what’s unique about being at Harvard, I always bring up this story,” Pu said. “The diverse set of people and cutting-edge technology available at Harvard certainly made this study possible.”

Story Source:

The above story is based on materials provided by Harvard University.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Human stem cells treat spinal cord injury side effects in mice

October 4, 2016
blank

Research into fly development provides insights into blood vessel formation

September 30, 2016

Fertility genes required for sperm stem cells

September 28, 2016

Regulatory RNA essential to DNA damage response

September 27, 2016
Please login to join discussion

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    40 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Deep sea surveys detect over five thousand new species in future mining hotspot

    35 shares
    Share 14 Tweet 9
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Carbon-based stimuli-responsive nanomaterials: classification and application

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In